Works matching IS 15391604 AND DT 2019 AND VI 18 AND IP 2
Results: 12
Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 126, doi. 10.1002/pst.1919
- By:
- Publication type:
- Article
Propensity‐score‐based priors for Bayesian augmented control design.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 223, doi. 10.1002/pst.1918
- By:
- Publication type:
- Article
A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 184, doi. 10.1002/pst.1913
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 123, doi. 10.1002/pst.1882
- Publication type:
- Article
Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 140, doi. 10.1002/pst.1935
- By:
- Publication type:
- Article
Investigation of the properties of the "switching decision rule" described in the Japanese guideline for human bioequivalence studies.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 260, doi. 10.1002/pst.1922
- By:
- Publication type:
- Article
Study design aspects and inter‐subject variability in longitudinal clinical phase II dose‐finding trials.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 248, doi. 10.1002/pst.1921
- By:
- Publication type:
- Article
On weighted composite scores for early Alzheimer's trials.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 239, doi. 10.1002/pst.1920
- By:
- Publication type:
- Article
Treatment effect quantification for time‐to‐event endpoints–Estimands, analysis strategies, and beyond.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 145, doi. 10.1002/pst.1917
- By:
- Publication type:
- Article
Phase II trial design with growth modulation index as the primary endpoint.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 212, doi. 10.1002/pst.1916
- By:
- Publication type:
- Article
On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 166, doi. 10.1002/pst.1915
- By:
- Publication type:
- Article
Bayesian sample size determination for phase IIA clinical trials using historical data and semi‐parametric prior's elicitation.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 2, p. 198, doi. 10.1002/pst.1914
- By:
- Publication type:
- Article